Radiopharm Theranostics Ltd (ASX:RAD) has strengthened its advisory credentials with the appointment of Dr Susann Brady-Kalnay PhD to its Scientific Advisory Board (SAB).
Dr Brady-Kalnay, a professor and distinguished faculty researcher in the Department of Molecular Biology & Microbiology at Case Western Reserve University (CWRU) and a Professor of Neurosciences, Pathology and member of the Case Comprehensive Cancer Center, will add weight to the development of RAD’s radiopharmaceutical products for diagnostic and therapeutic uses.
“Susann brings to the Scientific Advisory Board another excellent knowledge base and degree of experience in the molecular theranostic field," Radiopharm Theranostics managing director and CEO Riccardo Canevari said.
"Her work has been very unique in the industry and will complement the existing capabilities and assets we have at Radiopharm.”
Dr Susann Brady-Kalnay PhD will join Radiopharm's Scientific Advisory Board (SAB).
Highly credenitaled
Dr Brady-Kalnay is the founder and CSO of diagnostic and prognostic technology business NeoIndicate LLC and is trained in the fields of cell adhesion and signalling. Her research has focused on development and cancer-related signalling via Receptor Tyrosine Phosphatases.
She has been working to develop novel molecular diagnostic, prognostic and theranostic imaging agents and most recently has focused her studies on the existence of a key change in proteolysis of the cell-cell adhesion molecule receptor protein phosphatase PTPµ (PTPmu) in human cancer.
Dr Brady-Kalnay has also received significant recognition for her work including National Institutes of Health (NIH) grants and the renowned R01 Provocative Questions grant and an Academic Industrial Partnership grant from the National Cancer Institute (NCI).
She joins Dr Sara Hurvitz, Professor Eric Aboagye, Dr Johannes Notni, Dr Hong Hoi Ting and Dr David Ulmert on the SAB, chaired by Radiopharm’s chief medical officer Professor David Mozley.